Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Summit Therapeutics Inc. | sum-ex321_20201231x10k.htm |
| EX-31.2 - EX-31.2 - Summit Therapeutics Inc. | sum-ex312_20201231x10k.htm |
| EX-31.1 - EX-31.1 - Summit Therapeutics Inc. | sum-ex311_20201231x10k.htm |
| EX-21.1 - EX-21.1 - Summit Therapeutics Inc. | sum-ex211_20201231x10k.htm |
| EX-10.36 - EX-10.36 - Summit Therapeutics Inc. | sum-ex1036_20201231x10k.htm |
| EX-10.35 - EX-10.35 - Summit Therapeutics Inc. | sum-ex1035_20201231x10k.htm |
| 10-K - 10-K - Summit Therapeutics Inc. | smmt-20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-249316 and No. 333-251958) and Form S-8 (No. 333-249313 and No. 333-238582) of Summit Therapeutics Inc. of our report dated March 31, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Reading, United Kingdom
March 31, 2021